Hülya Güngel, Ozen Osmanbasoglu, Ebru Demet Aygit (Istanbul, Turkey)

Advantages:

To evaluate the clinical findings and treatment outcomes in patients with central retinal vein obstruction (CRVO).

Methods:

16 patients’ data that were followed more than 6 months were evaluated. Based on the angiographic findings patients were grouped as ischemic and non-ischemic CRVO. Visual acuity, OCT findings and treatment modalities were analyzed.

Effectiveness / Safety:

8 patients had non ischemic CRVO, 2 received 1 intravitreal triamcinolone acetonid injection (IVTA), 2 had 1 IVTA combined with bevacizumab injection, 1 underwent pars plana vitrectomy for vitreomacular traction and 1 patient received bevacizumab after 4 IVTA injections for intractable cystoid macular edema (CME) over a 2 year period. 2 patients with visual acuities 0,7 and 0,8 SR respectively was followed without treatment. 8 patients had ischemic CRVO, 3 had IVTA combined with bevacizumab injection, one had 1 bevacizumab injection, the other one had 1 IVTA injection, 5 patients (1 with disc neovascularization, 1 with rubeosis iridis at presentation) had pan retinal laser photocoagulation, 1 patient underwent epiretinal membrane (ERM) removal. Visual acuity improved in 4 patients and remained stable in the other 4 in non-ischemic group while remained stable in 5, improved in 2 and decreased in 1 patient in ischemic group. Regarding the last OCT findings, 6 patients had less than 300 µm and 2 had over 450 µm (1 ERM, 1 intractable CME) central foveal thickness in non-ischemic group. Central foveal thickness persisted over 350 µm despite treatment in 6 patients in ischemic group.

Take home message:

Intravitreal triamcinolone injection has favorable effect on visual acuity and OCT findings in non-ischemic CRVO. IVTA combined with bevacizumab was not found effective regarding visual acuity and OCT findings in ischemic CRVO.